Annual influenza epidemics, sporadic outbreaks of highly pathogenic avian strains and occasional pandemics continue to pose serious concerns for human health, livestock and poultry production. The 21st Century’s first pandemic of influenza H1N1 is a reminder of the importance of molecular methods in the management of responses to current and future threats. A number of laboratory methods are currently in use for influenza surveillance and diagnosis, and they include serological assays [1], conventional reverse-transcription (RT)-PCR or real-time RT (rRT)-PCR assays [2-5], pyrosequencing [6] or microarrays [7,8].

The last 2 years have seen an exponential rise in the amount of research funding made available for the development of rapid diagnostic devices and methods for infectious agents of medical importance, including influenza viruses. Each of these methods has certain advantages and limitations. For instance, some allow very rapid (<15 min) detection of influenza virus and recognition of type A versus type B but do not have subtyping capability, and some are limited to identifying one or two subtypes; other methods are more sensitive and conclusive but are more time consuming or not suited for a high-throughput format. The most commonly used molecular method for influenza diagnostics and identification is the rRT-PCR. Although sensitive, rapid and accurate, it is largely designed for characterization of the hemagglutinin (HA) and M genes. It does not allow subtyping of the neuraminidase (NA) and may not allow identification of emerging viruses with reassorted internal genes, such as the polymerases.

The selection of which method to use is, therefore, influenced by a combination of factors, including fitness for purpose, sensitivity, specificity, technical ease and cost. Complete genome sequencing coupled with phylogenetic analysis remains the gold standard for absolute influenza virus identification; however, this method is low throughput,
labor intensive and expensive. One of the new molecular methods is RT-PCR/electrospray ionization (ESI) mass spectrometry (MS), which was originally designed for microbial detection and characterization [9–11], and was later applied for influenza virus characterization [12,13]. The influenza RT-PCR/ESI-MS assay is a complementing tool to the array of assays currently in use, with its own advantages and certain limitations.

Identification of influenza virus using the RT-PCR/ESI-MS assay is based on the determination of the base counts of RT-PCR amplicons, representing highly variable loci on the influenza genome [12]. However, it is important to note that in its current format, the assay does not target the HA and NA genes, and the subtypes of these surface antigens of the influenza A viruses are inferred based on the analysis of the ‘core’ genes. Such an approach is not unique to this assay, and has been utilized previously in the development of other molecular assays intended for use in influenza diagnosis and surveillance [14,15]. In those studies, HA and NA subtypes of tested viruses were deduced based solely on M gene recognition using a low-density microarray. Inference of subtypes is not unusual in virus detection assays, especially in case of the NA, and most of the currently used assays, including the rRT-PCR, do not subtype the NA and rely mainly on subtyping the HA to infer the NA subtype.

Nevertheless, it is important to emphasize that inference of the HA and NA subtypes based on one or more internal genes is applicable only to stable lineages. The potential occurrence of reassortment presents a serious challenge to the methods that rely on deducing HA and NA subtypes. For instance, seasonal H1N2 viruses that acquired the HA gene from seasonal H1N1 viruses in 2001–2002 would be recognized as typical seasonal H3N2 viruses, since the internal genes were of H3N2 lineage [16]. Similarly, if an H1N1 pandemic virus would acquire a novel surface antigen – HA, from an avian H5N1 virus – it would still be recognized as a typical H1N1 pandemic virus.

**Principle of the influenza RT-PCR/ESI-MS assay & instrumentation**

The principle of the influenza RT-PCR/ESI-MS assay is based on the concept of triangulation, which combines the nucleotide base-composition (BC) signatures from multiple loci on the influenza genes to generate ‘genomic prints’ that are unique and specific to different virus groups or stable genetic lineages and allow their characterization. The assay involves several important steps that include sample collection and RNA isolation, the generation of amplicons using the Influenza Surveillance Kit (Abbott Molecular, IL, USA), including the primers, desalting and purification of PCR products, acquisition of ESI-MS signals and spectral analysis, and sample identification by comparison with a database (DB) of reference viruses that include predetermined BC signatures and/or genomic prints.

To date, all published studies have been performed on the T5000 instrument; however, Figure 1 is a photograph presentation of the Ibis T6000 biosensor instrument (also known as the PLEX-ID; Abbott Molecular) [101], in which all post-RT-PCR steps, including data analysis, are automated. The PLEX-ID represents a redesign of the original T5000 platform, and offers several key advantages over the preceding platform. Using a novel dual-probe ESI assembly, the PLEX-ID is capable of analyzing one well with PCR product every 30 s (twice as fast as the T5000) and, thus, completes analyzing an eight-well set of individual RT-PCR products for one specimen every 4 min. The anion-exchange resin-based desalting/purification chemistry employed by the PLEX-ID is the same as that used on the T5000 [17], although it is carried out on a rotating carousel that utilizes 22 identical spin cuvette modules. This configuration reduces both liquid waste and plastic-ware usage relative to the T5000 and affords enhanced reliability. The PLEX-ID input stacker allows the user to load 15 96-well PCR plates.
(accommodating up to 180 specimens analyzed for eight targets per load), and has an additional ‘stat’ drawer into which an assay plate can be placed for priority analysis. Noteworthy, unlike the T5000 platform, the PLEX-ID was designed and built under a rigorous US FDA-compliant design–control system, and is intended for eventual use in a clinical diagnostic capacity. At present, the PLEX-ID is a ‘research-use only’ device and is not cleared for diagnostics. The analytical sensitivity of the PLEX-ID platform was demonstrated to be 31–125 genome copies per PCR well [18].

Assay primer design
The primers are provided in the Influenza Surveillance Kit and were designed to target the core gene segment sequences from all influenza viruses of types A (subtypes HxNy, where x = 1–16, and y = 1–9), B and C, which are available in public domains. The gene sequences were aligned and eight amplification primer sets were chosen. The eight primer sets (Table 1) were designed from well-conserved regions, ranging from 101 to 129 bp and generate BC signatures that permit differentiation of the core genes of viruses that belong to stable genetic groups [12,13]. One primer pair, 2798, was designed to partially amplify PB1 from all known influenza viruses of all known origins (‘pan-influenza’). Five other sets of primers, 1266 (PA), 1279 (M1), 2775 (NS1) and 2777 (NS2), were designed to amplify sequences of only influenza viruses of type A (‘pan-influenza A’). For amplification of influenza B viruses only, two pairs of primers, 1261 (PB2) and 1275 (NP; ‘pan-influenza B’), were selected.

The primary constraint for primer design for this assay is the length limitation for the total PCR amplicon. For the accurate conversion of masses to base composition signatures, the amplicons have to be smaller than 150 bp. Furthermore, a multiple sequence alignment that shows regions of conservation of primer targets across multiple target sequences is necessary to achieve broad priming. Most of the other constraints are not different from other PCR design approaches. Target regions are evaluated on the basis of minimizing primer dimerization and hairpin formation, for example [10].

The primers were then tested and validated using 303 influenza samples from clinical specimens and cultured viruses [12,13]. More recently, the same assay was employed for analysis of over 750 viruses, including the H1N1 pandemic viruses [18].

RNA preparation & RT-PCR
The 96-well plate Influenza Surveillance Kit contains all the reagents required for the RT-PCR amplification. Only RNA samples, prepared as described elsewhere [12,18], were added. An example of plate layout is shown in Figure 2. In this format, each plate can be used to test 12 viruses. The conditions of the amplification are provided in detail elsewhere [12].

### Table 1. Details of the eight primer pairs contained in the influenza reverse-transcription PCR/electrospray ionization mass spectrometry assay kit.

| Primer ID | Gene segment targeted | Influenza type | Primer sequence | Amplicon length (bp) |
|-----------|-----------------------|---------------|-----------------|---------------------|
| 2798      | PB1                   | A, B, C       | F: TGTCCTGGAATGATGATGGGCATGTT | 128 |
|           |                       |               | R: TCACTCAGAGATTGGAGTCCATCCC |     |
| 1266      | NP                    | A             | F: TACATCCAGATGTGCACTGAACTCAAATCTCA | 111 |
|           |                       |               | R: TGTCGAAATGCAAGAGACACATTCTCTCTA |     |
| 1279      | M1                    | A             | F: TCTTGGCACAGTTGTATGGGCCCTCATAAC | 115 |
|           |                       |               | R: TGGAGAATCGAAATCTGCACA |     |
| 1287      | PA                    | A             | F: TGGGATTCCTTCTGTCATCCGA | 122 |
|           |                       |               | R: TGGAAAGATCTGCTGGAGACTTTTGT |     |
| 2775      | NS1                   | A             | F: TCCAGGACATACTGATGAGATGTCAAAAATGCA | 129 |
|           |                       |               | R: TGTTCCCCAAGCGAAATCTCGTA |     |
| 2777      | NS2                   | A             | F: TGTCAAAAATGCAATGGGGGTCCCTCATCG | 105 |
|           |                       |               | R: TCTATTCTGCTCTCCAAAGCGAAATCTCCTGTA |     |
| 1261      | PB2                   | B             | F: TCCCATGGTACTGCGATCATGCTTGA | 101 |
|           |                       |               | R: TATGAACTCAGCTGATGCTGGCTCTGCA |     |
| 1275      | NP                    | B             | F: TCCAATCATCACAGACGACAAACCTCTGG | 110 |
|           |                       |               | R: TCCGATATCGTCTCCTGCTGTTG |     |

Primer pair 2798 (PB1) allows amplification of a fragment from all influenza types A, B and C. Primers targeted to influenza type A viruses are capable of amplifying all influenza A viruses but do not cross amplify B and C types of influenza. Similarly, primers designed for the B type of viruses amplify all B viruses and not those of A and C types.

F: Forward; ID: Identification; R: Reverse.
Adapted from [12].
ESI-MS run, data acquisition & analysis
Following RT-PCR amplification of the targeted sequences, samples were transferred into the Ibis T5000 or T6000 (PLEX-ID) instruments, and automated PCR product desalting/purification and ESI-MS were performed [10, 17]. The mass spectrometer determines the weight of each amplicon with sufficient accuracy to allow measurement of the number of different nucleotides without ambiguity [11]. For each target, a BC signature was determined. Combinations of BC signatures from the six loci, in the case of influenza A (PB1, NP, M1, PA, NS1 and NS2), or three loci (PB1, PB2 and NP) for influenza B viruses, constitute a genomic print, and these were then compared with an existing library of genomic prints in a DB. These reference BC signatures (e.g., Figures 3 & 4), derived from sequences of known influenza A viruses, can be used to characterize the genes of viruses present in the samples tested. The criterion for an acceptable result using the RT-PCR/ESI-MS was set to be the detection of product in at least five of the six influenza A primer sets included in the kit [12]. In cases where one or more of the primer pairs did not amplify the targets, samples were further analyzed to determine the source of the failed amplification. The efficiency and robustness of the RT-PCR/ESI-MS assay are based on identification of the virus match (‘hit’) in the reference DB. This match refers to a single and/or multiple targets and a log-likelihood ratio is used to measure the goodness of this fit [10].

The RT-PCR/ESI-MS assay relies on external DBs only for naming the organisms and identifying them with the associated attributes, as defined in the reference sequences obtained from the various public domain DBs, such as Genbank or FluDB. The digital nature of the measurements made by this assay makes it capable of enhancing the existing data and, thus, provides a possibility of constantly updating the data. Theoretically, the DB could be updated as frequently as needed, although in practice, it is updated when there is a significant change in the underlying signature. For instance, the detection of the pandemic 2009H1N1 was accomplished without a DB update, although subsequent identification of this particular signature was accomplished with a DB update.

Applications
This section provides summaries of reported studies on the use of the influenza RT-PCR/ESI-MS assay. Of note, the studies reported in this article were performed at the WHO Collaborating Center for Surveillance, Epidemiology and Control of Influenza at the US CDC (GA, USA), using specimens collected in the USA and other countries, as detailed elsewhere [18], and by Ibis Biosciences, Inc., a subsidiary of Abbott Molecular (CA, USA). Details regarding the source and type of the different specimens tested at Ibis were described previously [12, 13]. Furthermore, the initial validation of
the influenza RT-PCR/ESI-MS assay was accomplished using 50 different grown influenza A virus isolates of avian, human, swine and equine origin, as well as human B viruses.

**Surveillance of human & avian influenza viruses**

The RT-PCR/ESI-MS assay was used to analyze over 650 clinical samples collected between 1999 and 2006 [12]. The results accurately predicted the presence of influenza viruses in approximately 240 specimens, while the remaining ones were negative. The detected viruses included A(H1N1), A(H3N2) and B. In addition, testing and the identification of 63 avian isolates, including high pathogenicity avian influenza virus H5N1 viruses, collected in Egypt and Asia, was reported by Sampath et al. Moreover, other viruses of swine origin were also tested and characterized [12,13].

The authors reported that virus types and subtypes inferred from the genomic prints determined based on the core genes concurred with those determined by HA inhibition (HI), rRT-PCR and conventional gene-sequencing assays, with over 97% sensitivity and 98% specificity [12]. In this study, an internal RNA control with a known number of copies was included in each of the eight target amplicon reactions. This allowed approximate quantitation of the amount of viral genome load in the samples tested.

After establishing that the RT-PCR/ESI-MS assay provided a rapid and high-throughput tool for influenza surveillance [12], it was used to analyze the different genetic lineages of the influenza type A(H3N2) viruses that circulated from 1996 to 2006. Sampath et al., in their study, used H3N2 viruses with complete genome sequences available in GenBank to construct a phylogenetic tree to enable the identification of different genetic groups [12]. The authors used a RT-PCR/ESI-MS assay to test the same set of viruses. The BC signature at each locus of the six influenza A targets analyzed for each virus was assigned a letter and the six letter sequence was termed ‘lineage’. The founder (ancestor) virus was assigned the lineage ‘AAAAAA’ as a reference. Sequence variations from the reference BC signatures at any of the six loci are referred to by a letter other than A [12]. The alignments of the six letters (lineages) from the 104 viruses were mapped onto the phylogenetic tree obtained from the full H3N2 genome sequences. The comparative analysis demonstrated a similar pattern of distribution of lineages identified by the RT-PCR/ESI-MS assay and the genetic groups (clades) determined based on complete genome sequencing [19]. Furthermore, BC signature-derived lineages of North American H3N2 viruses from the 2005–2006 influenza season were included and the analysis revealed the predominance of the AADFAA lineage among the 2005–2006 season viruses investigated. Interestingly, the same lineage was also found to be the most predominantly circulating lineage during the previous winter in the southern hemisphere. Those findings suggested that the 2004–2005 lineage was probably the precursor of the dominant 2005–2006 lineage. These data are in accordance with the studies by Simonsen and coworkers, who used full-genome sequencing and phylogenetic analyses to describe the genesis and spread of the N-lineage of adamantane-resistant H3N2 viruses [20], which correspond to those of the AADFAA lineage, determined by the RT-PCR/ESI-MS assay [12].
During the following 2006–2007 influenza season, new antigenic variants of H3N2 viruses, which are different from the vaccine strain A/Wisconsin/67/2005, emerged. These co-circulating genetic groups included both adamantine-sensitive and -resistant viruses [21–23]. Subsequently, the usefulness of the RT-PCR/ESI-MS assay in screening a large number of H3N2 viruses to identify major genetic lineages in circulation was assessed [18]. For this purpose, 65 viruses were analyzed and were all represented by 20 unique genomic prints [18]. The most dominant genomic prints among the adamantine-resistant viruses were AADFAA, CCDFAA and CCLFAA. Of note, the AADFAA genomic print was shared between H3N2 viruses that circulated...
in prior seasons, specifically the N-lineage [12,20]. Comparison of the RT-PCR/ESI-MS results with full-genome sequencing and phylogenetic data of the same 65 viruses showed that the 20 representative genomic prints identified clustered according to the four genetic lineages (A–D) determined by phylogenetic analysis [24].

Analysis of 95 H3N2 viruses collected during the following influenza season (2008–2009), using the RT-PCR/ESI-MS assay, revealed that they all retained the genomic prints CCDFAA or CCLFAA, which are characteristic of the D lineage, with no apparent evidence of major genetic changes based on this assay. These observations were consistent with the results obtained based on phylogenetic analyses [24].

Collectively, these studies suggested that the RT-PCR/ESI-MS assay could serve as a primary screening tool to identify emerging variants among co-circulating viruses, and as a valuable tool for the rapid testing of large numbers of viruses. Such information could be valuable in decision making and for recommendations on new vaccine strain selection and M2 antiviral drug ( adamantanes) usage.

**Analysis of H1N1 virus clades & characterization of reassortant dual-resistant H1N1 viruses**

The vast majority of recently circulating seasonal (pre-pandemic) H1N1 viruses are either resistant to adamantane drugs (clade 2C) or to NA inhibitors (clade 2B) [25–27]. However, the genesis and spread of dual-resistant viruses through reassortment between these two co-circulating clades are of public health concern. Indeed, a number of viruses resistant to both adamantanes and oseltamivir were detected in Asia and North America [25,26,28].

The RT-PCR/ESI-MS assay’s ability to identify seasonal H1N1 viruses and the clades to which they belong and to recognize those emerging from reassortment between the two clades was assessed [18]. Viruses A/South Dakota/06/2007 (clade 2B), A/Colorado/UR06–0053/2007 (clade 2C) and A/Texas/57/2009 (reassortant 2B/2C clades) with experimentally predetermined genomic prints were used as reference strains for the identification of tested samples. In total, 37 seasonal H1N1 viruses were analyzed, and 23 of them were determined to belong to clade 2B, matching the A/South Dakota/06/2007 genomic print. Five were identified as clade 2C viruses based on their genomic prints. Seven viruses were demonstrated to match the genomic print of A/Texas/57/2009, which was previously characterized as a reassortant virus resistant to both the adamantanes and oseltamivir [28]; all seven viruses were demonstrated to contain a hybrid of BC signatures from both clades 2B and 2C. Genome sequencing, complemented with phylogenetic analyses, revealed that the majority of the dual-resistant viruses were of clade 2B that acquired the M genes from clade 2C viruses, rendering the reassortant virus resistant to both the adamantanes and oseltamivir drugs [25,26,28]. The two remaining viruses had genomic prints that did not match those from any of the three reference viruses. Of note, the BC signatures obtained from NS1 and NS2 targets in the current RT-PCR/ESI-MS assay did not allow distinction between viruses of clades 2B and 2C.

**Detection of emerging or unusual influenza A viruses**

More recently, using the RT-PCR/ESI-MS assay, the Naval Health Research Center (NHRC; San Diego, CA, USA), in collaboration with the CDC’s Border Infectious Disease Surveillance Project, detected one of the first cases of ‘unsubtypable’ influenza A viruses (by rRT-PCR), which later became known as the H1N1 pandemic virus [29,30]. The virus had unique BC signatures, which were close matches to BC signatures of different genes of viruses of human, swine, and avian origins. While the results obtained using this assay were not (and could not be) as definitive as full-genome sequence analyses [31], they undoubtedly indicated the presence of an atypical influenza A virus. Soon after the genome sequences of the viruses from the first cases were available, and similar strains were detected in other locations in North America [32], the unique genomic print of the prototype virus (known as A/California/04/2009) was added to the Ibis Biosciences’ DB and became the reference virus for the characterization of core genes of subsequent pandemic viruses. The RT-PCR/ESI-MS assay was also independently used at the CDC during the early stages of the 2009 pandemic to confirm its ability to reliably identify the core genes of the newly emerged virus and for monitoring potential changes in the internal gene composition due to reassortment. To this end, 285 H1N1 pandemic viruses, including 209 clinical samples, were tested. The results were, overall, consistent with those obtained using the CDC rRT-PCR assay [18,102], with approximately 94% sensitivity and 97% specificity. The findings of this study suggested no significant variations in target sequences among these viruses compared with the reference virus A/California/04/2009 [18].

**Differentiation between live-attenuated influenza vaccine strains from wild-type viruses**

The RT-PCR/ESI-MS assay was further used to successfully differentiate between the live-attenuated influenza vaccine (LAIV) strains and the wild-type viruses [18]. RT-PCR/ESI-MS testing of a sample submitted to the CDC for routine characterization (by rRT-PCR) revealed a genomic print that was distinct from those of wild-type H1N1 pandemic, seasonal H1N1 and seasonal H3N2 viruses, as well as other viruses of animal origin. As expected for the LAIV strain of the H1N1 pandemic, the genomic print matched that of A/Ann Arbor/6/60 (H2N2), the master donor of the core genes, present in the formulation of the H1N1 pandemic LAIV. The RT-PCR/ESI-MS assay results confirmed those obtained based on rRT-PCR and gene-sequencing data [Shu B, Pers. Comm.]

**Expert commentary**

The RT-PCR/ESI-MS technology was first developed and used in 2005 for rapid microbial detection and identification of clinical specimens and environmental samples [9–11]. Rapidly, the method found its usage widen to include detection of biothreat agents and bacterial genotyping, as well as virus characterization (e.g., alphaviruses, coronaviruses and influenza viruses) [9–13,33,34]. In the field of influenza, a RT-PCR/ESI-MS assay was designed to target the core gene segments and not the highly variable surface antigen-coding genes, HA and NA [12,13]. Testing of the primer
sets demonstrated that they could generate PCR amplicons from a wide variety of influenza virus types/subtypes for subsequent BC signature and genomic print determination based on the core genes. The generated genomic prints are information rich and allow differentiation among the core genes of the various influenza types and subtypes [12]. The assay was subsequently used in the analysis of different genetic groups of seasonal H3N2 and H1N1 influenza viruses [12,18] and, more significantly, was used to detect one of the first two cases of the now known H1N1 pandemic virus [29,30]. It is worth noting that the initial identification of the origin of each gene of this complex reassortant virus was deficient. This inaccuracy in determining the exact sources of each gene was primarily owing to the absence of adequate swine reference sequences in the DB used for analysis. It is also essential to emphasize that the lack of systematic surveillance of swine populations for influenza added more complexity and difficulty to the identification of the closest gene ancestors of the H1N1 pandemic virus [31,35], a factor not unique to the RT-PCR/ESI-MS assay.

It is important to note that influenza A viruses consist of a segmented negative-sense RNA genome, which is prone to acquisition of point mutations and gene reassortment [36]. To date, 16 HA and nine NA subtypes of influenza A viruses have been characterized, and all have been isolated from aquatic birds [37–39]. Therefore, aquatic birds are considered the primary reservoirs for all influenza A virus subtypes. It is believed that viruses from these birds can cross species barriers and infect a large variety of animals, including humans, pigs, dogs, horses, sea mammals and birds, and result in the genesis of novel viruses [37–39].

Owing to the diversity and complexity of influenza A viruses’ hosts, any attempt to determine the exact origin of the individual components of the genome of novel influenza viruses should be carried out with great caution, especially if reassortment of gene segments is involved.

The development of molecular methods that allow the rapid detection and identification of novel or unusual influenza viruses in humans is central in combating and containing future epidemics and potential pandemics. The RT-PCR/ESI-MS assay lends itself for such needs and fits a niche with the potential for significant expansion. The recent findings that reassortment between H5N1 and seasonal H3N2 viruses could result in highly virulent strains [41–43] and the isolation of a triple reassortant swine H1N1 virus that acquired the HA and NA genes from human seasonal virus [44] underline the importance of the availability of molecular tools, including the RT-PCR/ESI-MS assay, which allow rapid identification of novel strains with such complex genomes.

When compared with the more widely used rRT-PCR-based assays [2–5], which typically provide more rapid and specific results, the RT-PCR/ESI-MS assay is better suited for high-throughput settings and broad-range identification. It has the advantage of simultaneously analyzing six gene segments or more. Furthermore, the rRT-PCR-based methods would require gene sequencing in addition to phylogenetic analysis for final confirmation. Often, the goal of most rRT-PCR assays is more definitive and seeks to determine whether a specific strain (e.g., an H3N2, H1N1, H5N1 or B virus) is present in a sample. On the other hand, the RT-PCR/ESI-MS assay aims at identifying ‘what is in the sample to be analyzed’, which provides an all-inclusive, although less-precise, answer. For instance, if the sample contains a virus that has been characterized previously with a unique genomic print in a reference DB, it will be identified as such. If it is a novel virus without a match in the DB, the assay will indicate that this is an atypical virus and the user could follow-up with further characterization. Such was the approach with the initial cases of the H1N1 pandemic virus [29,30]. It should be noted that the accuracy and high-throughput nature of the RT-PCR/ESI-MS assay makes it well suited for screening large numbers of viruses for genome changes, in addition to occurrences of segment reassortment. Finally, the sensitivity of the RT-PCR/ESI-MS assay, which is determined by the RT-PCR step, allows sample testing directly from clinical specimens without the need of culturing viruses, thus making it both time efficient and cost effective.

Although the RT-PCR/ESI-MS assay can be useful in influenza virus research, it is not without limitations, the most noticeable being the lack of targets for the two surface antigens, HA and NA, in the currently available Influenza Surveillance Kit. It is based on results obtained from the core genes that the HA and NA subtypes are deduced. Even though such a correlation between the core genes and the HA and NA subtypes does exist in the vast majority of viruses circulating in humans, it is significant to note that this correlation can be compromised due to natural reassortment events or to artificial ones, such as generation of LAIV strains. Additionally, the kit does not include primers to amplify and analyze the PB2 gene of influenza A viruses. It is worth noting that these drawbacks do not imply flaws in the technology itself but are a result of the purpose for which the assay was first designed. At that time, the goal was to demonstrate that the assay provides accurate, rapid and high-throughput detection of any influenza virus in a sample. We believe the assay could be tailored to suit more specific needs of influenza genomics, surveillance and diagnostics. Another limitation of the RT-PCR/ESI-MS assay, as currently used, is the dependency of the users on the instrument vendor for data analysis. It would be beneficial if the end users could readily access the DB used for analysis and keep it up-to-date with new reference BC signatures, genomic prints and relevant virus attributes, thereby maintaining the DB content as relevant and current.

Another shortcoming of the assays described in this study is the lack of testing for anti-influenza drug-resistance markers. However, the next-generation influenza assays in Abbott’s portfolio include detection of some known markers of antiviral resistance. Nevertheless, this is not a platform limitation, since microbial resistance testing and characterization using PLEX-ID has been demonstrated for bacteria [45–47].

Noteworthy, type B influenza viruses were not discussed extensively in this article because of the limited data on the use of the RT-PCR/ESI-MS assay in analysis of these viruses. Nevertheless, it is important to emphasize that the assay is capable of detecting such viruses.

Five-year view
Since its introduction, the use of the RT-PCR/ESI-MS technology in pathogen characterization is on the increase. Although
the technology was initially intended for bacterial detection, it was quickly adapted for other applications, including influenza virus identification. In the next 5 years, the influenza RT-PCR/ESI-MS assay, in particular, is likely to gain wider usage and acceptance, especially if additional tailored kits, such as the ‘2009 H1N1 Pandemic Diagnostics Kit’ currently being evaluated, become available. The influenza RT-PCR/ESI-MS assay could, in the future, be refined by designing multiple sets of primers to target each gene, or by including primers targeting the HA, NA and PB2 of influenza A viruses, as well as other primers to address specific questions. For example, new assays could be designed for the analysis of gene reassortment among influenza viruses in pigs, or for the investigation of reassortment between the H1N1 pandemic and highly pathogenic H5N1 viruses and determination of which gene segments are involved in a particular reassortment event.

In the near future, the RT-PCR-ESI-MS assay has the potential of becoming a valuable addition to the array of tools used in influenza virus surveillance and diagnostics. Recently, the kit currently in use was customized to develop a diagnostic assay for the H1N1 pandemic viruses. Validation, approval and expansion of this diagnostic kit to include other subtypes could be of significant clinical relevance, especially since the assay can be performed directly on clinical specimens. Availability of such capabilities would aid in improving the management of patients.

Figure 5 illustrates the design of this new assay. All eight segments were targeted including the PB2 for influenza A viruses, and HA and NA, which are targeted to the H1N1 pandemic. The PB2 and HA primers replaced the influenza A virus NS2 and influenza B virus NP targets, respectively, while the NA primers were duplexed with those targeting the influenza B virus PB2 gene. Details of the primers in the new assay are presented in Table 2. Such improvements and refinements in the assay can be challenging; however, they could be valuable in providing a rapid ‘snap shot’ of the entire genome with a high-throughput method and, subsequently, a more in-depth virus characterization using the assay’s built-in neural network capability.

Acknowledgements
The authors thank Alexander Klimov, Michael Shaw and members of the Molecular Epidemiology Team from the Influenza Division, CDC, for fruitful discussions.

| Samples |
|---------|
| 1       | 2       | 3       | 4       | 5       | 6       | 7       | 8       | 9       | 10      | 11      | 12      |
| Pan-influenza-PBI |
| A       | 2798    | 2798    | 2798    | 2798    | 2798    | 2798    | 2798    | 2798    | 2798    | 2798    | 2798    |
| Influenza A-NP |
| B       | 1266    | 1266    | 1266    | 1266    | 1266    | 1266    | 1266    | 1266    | 1266    | 1266    | 1266    |
| Influenza A-M1 |
| C       | 1279    | 1279    | 1279    | 1279    | 1279    | 1279    | 1279    | 1279    | 1279    | 1279    | 1279    |
| Influenza A-PA |
| D       | 1287    | 1287    | 1287    | 1287    | 1287    | 1287    | 1287    | 1287    | 1287    | 1287    | 1287    |
| Influenza A-NSI |
| E       | 2775    | 2775    | 2775    | 2775    | 2775    | 2775    | 2775    | 2775    | 2775    | 2775    | 2775    |
| Influenza A-PB2 |
| F       | 1259    | 1259    | 1259    | 1259    | 1259    | 1259    | 1259    | 1259    | 1259    | 1259    | 1259    |
| H1N1pdm-HA |
| G       | 5101    | 5101    | 5101    | 5101    | 5101    | 5101    | 5101    | 5101    | 5101    | 5101    | 5101    |
| Influenza B-PB2 |
| H       | 1261    | 1261    | 1261    | 1261    | 1261    | 1261    | 1261    | 1261    | 1261    | 1261    | 1261    |
| H1N1pdm-NA |

Figure 5. Customized reverse-transcription-PCR/electrospray ionization mass spectrometry assay for the diagnosis of the H1N1 pandemic virus. New influenza kit under evaluation features replacement of the influenza A NS2 and influenza B NP primers used in the old version with influenza A PB2 (1259) and the H1N1 pandemic virus HA (5101), respectively. Additionally, H1N1 pandemic NA primers (4998) are duplexed with the influenza B PB2 gene primer set in the last row (H1–H12) of the plate. Details on the new primers are shown in Table 2. The remaining primers are the same as those described in Figure 1 and Table 1.

H: Hemagglutinin; N: Neuraminidase.
Review

Deyde, Sampath & Gubareva

Financial & competing interests disclosure
Rangarajan Sampath is an employee of the Ibis/Abbott Company that developed the Influenza reverse-transcription PCR/electrospray ionization mass spectrometry assay. This statement is made in the interest of full disclosure and not because the authors consider this to be a conflict of interest. The study was funded by the Centers for Disease Control and Prevention. The funder had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. The manuscript was cleared for submission to the journal following the CDC’s standard operating procedures. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.

Key issues

- The influenza reverse-transcription (RT)-PCR/electrospray ionization (ESI) mass spectrometry (MS) assay kit provides a rapid and broad-range influenza virus ‘core’ gene-characterization tool.
- The assay is based on ESI-MS and analysis of the base composition of RT-PCR amplicons generated using primers targeted to highly conserved regions flanking highly variable sequences in the influenza core’s genes.
- The assay is high throughput and allows analysis of approximately 300 samples in 24 h (from specimen receipt to reporting results).
- One of the first two human cases of a reassortant virus, now known as the H1N1 pandemic virus, was identified using this assay.
- The RT-PCR/ESI-MS assay, in its current format, is designed for the broad-range detection of influenza A and B viruses based on the core genes, but can be tailored for the specific needs of surveillance, as well as for diagnostic purposes.
- The premise of this assay is that it not only permits rapid characterization of previously known viruses, but it also detects unusual and emerging influenza viruses, based on their core genes’ signatures.
- The level of accuracy in virus characterization depends upon the reference base-composition signatures and genomic prints present in the database at the time of analysis.

Table 2. H1N1 pandemic virus reverse-transcription PCR/electrospray ionization mass spectrometry diagnostics assay primer sets.

| Primer ID | Gene segment targeted | Influenza | Primer sequence | Amplicon length (bp) |
|-----------|-----------------------|-----------|-----------------|---------------------|
| 2798      | PB1                   | A, B, C   | F: TGTCCTGGAATGATGATGGGCACTGGT | 128 |
|           |                       |           | R: TCATCAGAGGATGGGAGTCATCCCC  |       |
| 1266      | NP                    | A         | F: TACATCCAGATGTCAGTCAAACTCAA | 111 |
|           |                       |           | R: TGGTTCAAAATGCAACCATTCTCTTA  |       |
| 1279      | M1                    | A         | F: TCTTGCGAGTGATGATGGCACTGCA  | 115 |
|           |                       |           | R: TGGGAGTCAGCAATCAGTCACA      |       |
| 1287      | PA                    | A         | F: TTGGATTCTTCTGCTAGTCGGA      | 122 |
|           |                       |           | R: TTGGGAAGTICGGTGGAGACTTTTG   |       |
| 2775      | NS1                   | A         | F: TCCAGGCACATCAGTGAAGTATCGA   | 129 |
|           |                       |           | R: TGGTTCCCAAGGCUAACTCTCTGA    |       |
| 1259      | PB2                   | A         | F: TACCACCTGGAGGACATGCGATAAT   | 105 |
|           |                       |           | R: TGGGATATTTCATTGCATCAGTCATCC |       |
| 5101      | HA                    | A/H1N1 pandemic | F: TGACAGGATGGTGAAGTGATGTCG  | 103 |
|           |                       |           | R: TATCAGCTGCTAGTATGGATGCTCG  |       |
| 4998      | NA†                   | A/H1N1 pandemic | F: TGGATCGATGGATGCTGGCTGGCTGG| 73  |
|           |                       |           | R: TATCAACTGAGCTGATGCTGCTGCTG |       |
| 1261      | PB2†                  | B         | F: TCCATGGATTGGGATACTGACATGCTGA| 101 |
|           |                       |           | R: TATGAACTGAGCGATGGGATGTCGCTG |       |

Primer pairs targeting PB1, NP, M1, PA and NS1 are the same as the ones described in Table 1. Primer set 1259 is added to target all influenza A viruses. Primer pairs targeting hemagglutinin and neuraminidase are designed to identify the H1N1 pandemic viruses.

†These two primer sets were duplexed (included) in the same well.
F: Forward; ID: Identification; R: Reverse.
References

Papers of special note have been highlighted as:

• of considerable interest

1 Julkunen I, Pyhala R, Hovi T. Enzyme immunoassay, complement fixation and hemagglutination inhibition tests in the diagnosis of influenza A and B virus infections. Purified hemagglutinin in subtype-specific diagnosis. J. Viral. Methods 10(1), 75–84 (1985).

2 Chidlow G, Harnett G, Williams S, Levy A, Speers D, Smith DW. Duplex real-time RT-PCR assays for the rapid detection and identification of pandemic (H1N1) 2009 and seasonal influenza viruses A/H1, A/H3 and B. J. Clin. Microbiol. 48(3), 862–866 (2010).

3 Pabbaraju K, Wong S, Wong AA et al. Design and validation of real-time reverse transcription-PCR assays for detection of pandemic (H1N1) 2009 virus. J. Clin. Microbiol. 47(11), 3454–3460 (2009).

4 Whitey DM, Bialasiewicz S, Bletterly C et al. Detection of novel influenza A(H1N1) virus by real-time RT-PCR. J. Clin. Virol. 45(3), 203–204 (2009).

5 Yang JR, Lo J, Liu JL et al. Rapid SYBR green I and modified probe real-time reverse transcription-PCR assays identify influenza H1N1 viruses and distinguish between pandemic and seasonal strains. J. Clin. Microbiol. 47(11), 3714–3716 (2009).

6 Bright RA, Medina MJ, Xu X et al. Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet 366, 1175–1181 (2005).

7 Kessler N, Ferraris O, Palmer K, Marsh W, Steel A. Use of the DNA flow-thru chip, a three-dimensional biochip, for typing and subtyping of influenza viruses. J. Clin. Microbiol. 42(5), 2173–2185 (2004).

8 Metzgar D, Myers CA, Russell KL et al. Single assay for simultaneous detection and differential identification of human and avian influenza virus types, subtypes, and emergent variants. PLoS ONE 5(2), e5995 (2010).

9 Ecker DJ, Sampath R, Blyn LB et al. Rapid identification and strain-typing of respiratory pathogens for epidemic surveillance. Proc. Natl Acad. Sci. USA 102(22), 8012–8017 (2005).

10 Ecker DJ, Drader J, Gutierrez J et al. The Ibis T5000 Universal Biosensor: an automated platform for pathogen identification and strain typing. J. Assoc. Lab. Automat. 11(6), 341–351 (2006).

11 Hofstandler SA, Sampath R, Blyn LB et al. TIGER: the universal biosensor. Int. J. Mass Spectrom. 242, 23–41 (2005).

• First report describing application of reverse-transcription PCR (RT-PCR)/electrospray ionization mass spectrometry (ESI-MS).

12 Sampath R, Russell KL, Massire C et al. Global surveillance of emerging Influenza virus genotypes by mass spectrometry. PLoS ONE 2(5), e489 (2007).

• Applied RT-PCR/ESI-MS for influenza viruses surveillance.

13 Sampath R, Hall TA, Massire C et al. Rapid identification of emerging infectious agents using PCR and electrospray ionization mass spectrometry. Ann. NY Acad. Sci. 1102, 109–120 (2007).

• First report describing application of RT-PCR/ESI-MS in the field of influenza.

14 Dawson ED, Moore CL, Smagala JA et al. MChip: a tool for influenza surveillance. Anal. Chem. 78(22), 7610–7615 (2006).

15 Mehlmann M, Bonner AB, Williams JV et al. Comparison of the MChip to viral culture, reverse transcription-PCR, and the QuickVue influenza A+B test for rapid diagnosis of influenza. J. Clin. Microbiol. 45(4), 1234–1237 (2007).

16 Xu X, Smith CB, Mungall BA et al. Intercontinental circulation of human influenza A(H1N1) reassortant viruses during the 2001–2002 influenza season. J. Infect. Dis. 186(10), 1490–1493 (2002).

17 Jiang Y, Hofstandler SA. A highly efficient and automated method of purifying and desalting PCR products for analysis by electrospray ionization mass spectrometry. Anal. Biochem. 316(1), 50–57 (2003).

18 Deyde YM, Sampath R, Garten R et al. Genomic signature-based identification of influenza a virus using electro-spray ionization mass spectrometry (RT-PCR/ESI-MS) technology. PLoS ONE 5(10), e13293 (2010).

19 Holmes EC, Ghedin E, Miller N et al. Whole-genome analysis of human influenza A virus reveals multiple persistent lineages and reassortment among recent H3N2 viruses. PLoS Biol. 3(9), e300 (2005).

20 Simonsen L, Viboud C, Grenfell BT et al. The genesis and spread of reassortment human influenza A/H3N2 viruses conferring adamantane resistance. Mol. Biol. Evol. 24(8), 1811–1820 (2007).

21 Deyde VM, Garten R, Sheu TG, Gubareva LV, Klimov AI. Letter to the Editor: reply to Saito et al. J. Infect. Dis. 197, 632–633 (2008).

22 Nelson MI, Edelman L, Spiro DJ et al. Molecular epidemiology of A/H3N2 and A/H1N1 influenza virus during a single epidemic season in the United States. PLoS Pathog. 4(8), e1000133 (2008).

23 Pabbaraju K, Ho KC, Wong S et al. Admantane resistance in circulating human influenza A viruses from Alberta, Canada (1970–2007). Antiviral Res. 79(2), 81–86 (2008).

24 Deyde V, Garten R, Sheu T et al. Genomic events underlying the changes in adamantane resistance among influenza A(H3N2) viruses during 2006–2008. Influenza Other Resp. Viruses 3(6), 297–314 (2009).

25 Cheng PK, Leung TW, Ho EC et al. Oseltamivir- and amantadine-resistant influenza viruses A (H1N1). Emerg. Infect. Dis. 15(6), 966–968 (2009).

26 Cheng PK, To AP, Leung TW, Leung PC, Lee CW, Lim WW. Oseltamivir- and amantadine-resistant influenza virus A (H1N1). Emerg. Infect. Dis. 16(1), 155–156 (2010).

27 Meijer A, Lackenby A, Hungnes O et al. Oseltamivir-resistant influenza virus A (H1N1), Europe, 2007–2008 season. Emerg. Infect. Dis. 15(4), 552–560 (2009).

28 Sheu TG, Fry AM, Garten RJ et al. Dual resistance to adamantanes and oseltamivir among seasonal influenza A (H1N1) viruses: 2008–2010. J. Infect. Dis. (2010) (In press).

29 Faix DJ, Sherman SS, Waterman SH. Rapid-test sensitivity for novel swine-origin influenza A (H1N1) virus in humans. N. Engl. J. Med. 361(7), 728–729 (2009).

• Reports that the RT-PCR/ESI-MS influenza assay was used to detect the first case of the 2009 H1N1 pandemic.

30 Metagar D, Baynes D, Myers CA et al. Initial identification and characterization of an emerging zoonotic influenza virus prior to pandemic spread. J. Clin. Microbiol. 48(11), 4228–4234 (2010).

31 Garten RJ, Davis CT, Russell CA et al. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science 325(5937), 197–201 (2009).

32 Centers for Disease Control and Prevention (CDC). Swine influenza A (H1N1) infection in two children – southern California, March–April 2009. Morb. Mortal. Wkly Rep. 58(15), 400–402 (2009).

www.expert-reviews.com
33 Eshoo MW, Whitehouse CA, Zoll ST et al. Direct broad-range detection of alphaviruses in mosquito extracts. *Virology* 368(2), 286–295 (2007).

34 Eshoo MW, Whitehouse CA, Nalca A et al. Rapid and high-throughput pan-Orthopoxvirus detection and identification using PCR and mass spectrometry. *PLoS ONE* 4(7), e6342 (2009).

35 Smith GJ, Vijaykrishna D, Bahl J et al. Origins and evolutionary genomics of the 2009 swine-origin H1N1 influenza A epidemic. *Nature* 459(7250), 1122–1125 (2009).

36 Nelson MI, Holmes EC. The evolution of epidemic influenza. *Nat. Rev. Genet.* 8(3), 196–205 (2007).

37 Alexander DJ. A review of avian influenza in different bird species. *Vet. Microbiol.* 74, 3–13 (2000).

38 Fouchier RA, Munster V, Wallensten A et al. Characterization of a novel influenza A virus hemagglutinin subtype (H16) obtained from black-headed gulls. *J. Virol.* 79, 2814–2822 (2005).

39 Webster RG, Bean WJ, Gorman OT, Chambers TM, Kawaoka Y. Evolution and ecology of influenza A viruses. *Microbiol. Rev.* 56, 152–179 (1992).

40 Ma W, Lager KM, Lekcharoensuk P et al. Viral reassortment and transmission after coinfection of pigs with classical H1N1 and triple reassortant H3N2 swine influenza viruses. *J. Gen. Virol.* 91(Pt 9), 2314–2321 (2010).

41 Chen LM, Davis CT, Zhou H, Cox NJ, Donis RO. Genetic compatibility and virulence of reassortants derived from contemporary avian H5N1 and human H3N2 influenza A viruses. *PLoS Pathog.* 4(5), e1000072 (2008).

42 Jackson S, Van HN, Chen LM et al. Reassortment between avian H5N1 and human H3N2 influenza viruses in ferrets: a public health risk assessment. *J. Virol.* 83(16), 8131–8140 (2009).

43 Li C, Hatta M, Nidom CA et al. Reassortment between avian H5N1 and human H3N2 influenza viruses creates hybrid viruses with substantial virulence. *Proc. Natl Acad. Sci. USA* 107(10), 4687–4692 (2010).

44 Bastien N, Antonishyn NA, Brandt K et al. Human infection with a triple-reassortant swine influenza A(H1N1) virus containing the hemagglutinin and neuraminidase genes of seasonal influenza virus. *J. Infect. Dis.* 201(8), 1178–1182 (2010).

45 Ecker DJ, Massire C, Blyn LB et al. Molecular genotyping of microbes by multilocus PCR and mass spectrometry: a new tool for hospital infection control and public health surveillance. *Methods Mol. Biol.* 551, 71–87 (2009).

46 Endimiani A, Hujer KM, Hujer AM et al. Rapid identification of bla KPC-possessing *Enterobacteriaceae* by PCR/electrospray ionization-mass spectrometry. *J. Antimicrob. Chemother.* 65, 1833–1834 (2010).

47 Hall TA, Sampath R, Blyn LB et al. Rapid molecular genotyping and clonal complex assignment of *Staphylococcus aureus* isolates by PCR coupled to electrospray ionization-mass spectrometry. *J. Clin. Microbiol.* 47, 1733–1741 (2009).

**Websites**

101 Ibis Biosciences www.ibisbiosciences.com

102 WHO. Swine flu www.who.int/csr/resources/publications/swineflu/CDCrealtimERTPCRprotocol_20090428.pdf